The BSAC standardized disc susceptibility testing method remains unchanged, but there are considerable changes to the interpretative criteria due to continuing harmonization with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC breakpoints. There are a number of agents for which interpretative criteria have been removed. These MIC and/or zone diameter breakpoints will be published on the BSAC web site as a 'Legacy' table; they may be used for research or comparative purposes, but are not recommended for clinical management. Notably, testing of staphylococci for susceptibility to glycopeptides by disc diffusion has been removed because this method has been found to be unreliable, particularly for the detection of low-level resistance; low-level vancomycin resistance in staphylococci is increasingly deemed to be of clinical relevance. The tables for anaerobes have been expanded to include MIC breakpoints that have been determined by EUCAST. There are currently no zone diameter breakpoints for these organisms and an MIC method is recommended if susceptibility testing is required.
Introduction
Version 10 of the BSAC standardized disc susceptibility testing method has been published on the BSAC web site (http://www. bsac.org.uk/Susceptibility+Testing/GUIDELINES+Standardized+ Disc+Susceptibility+Testing+Method). The basic disc susceptibility testing method remains unchanged, 1 but there have been a number of alterations to the interpretive criteria due to continuing harmonization with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2 MIC breakpoints, and constant efforts to improve the reliability and clinical applicability of the guidance.
Instances where changes have been made to the interpretative criteria for aerobic bacteria tested with different antibiotics are shown in Table 1 . The change introduced may have been to the MIC breakpoint, the zone diameter interpretation and/or the comment column of the Table, while in other instances (e.g. piperacillin/tazobactam for Pseudomonas spp.) a review of the data has led to alteration of the zone criteria although the MIC breakpoint remains the same. However, there are also instances (e.g. cefepime for Enterobacteriaceae) where the MIC breakpoint has been altered but no change in zone diameter criteria is required. This is because zone diameter criteria are determined using population distributions of zone diameters for organisms with different MICs and resistance mechanisms, to select the most effective and reproducible breakpoint to differentiate organisms within different MIC susceptibility categories rather than simple regression. In certain cases, the BSAC has maintained a breakpoint where one has not been determined by EUCAST; this is usually where there has been no requirement for a Europe-wide breakpoint for a compound due to limited availability of the compound in different countries (e.g. temocillin). Table 2 shows the changes to the interpretive criteria for anaerobic bacteria. A number of new MIC breakpoints that have been determined by EUCAST have been added. There are currently no zone diameter criteria for these agents and an MIC method is recommended if susceptibility testing is required. For the few compounds where disc criteria exist, it is highlighted that these only apply to Bacteroides fragilis, Bacteroides thetaiotaomicron or Clostridium perfringens, as indicated.
There are a number of compounds, listed in Table 3 , for which interpretive criteria have been removed. This is either because the species is considered a poor target for therapy with the drug (e.g. Pseudomonas spp. and moxifloxacin), susceptibility can be most effectively inferred from susceptibility to other agents (e.g. ertapenem susceptibility of b-haemolytic streptococci can be inferred from the penicillin result), or the agent is no longer widely available or used (e.g. carbenicillin). These MIC breakpoints and zone diameter criteria will be published separately on the BSAC web site as a 'Legacy' table. They may be used for research or comparative purposes, but it is not recommended to use the legacy data for clinical management as their applicability is uncertain and the breakpoints will no longer be maintained. (Table 4 Pseudomonas spp. (Table 6 
Notable changes in Version 10
Carbapenem testing of Enterobacteriaceae and Pseudomonas spp. (Tables 4 and 6) The emergence and spread of carbapenemase-mediated resistance in these organisms is currently causing concern. The MIC (Table 13 ) (Table 14) Penicillin
Neisseria meningitidis (Table 15 )
Haemophilus influenzae (Table 16 )
Campylobacter spp. (Table 18)  Quinolones  N  N  N  Erythromycin  Y   Y, changes to the table; N, no changes to the table; UTI, urinary tract infection; ESBL, extended-spectrum b-lactamase.
Andrews & Howe breakpoints and disc criteria have not changed, but guidance from the HPA 3 is highlighted.
Colistin testing of Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp. (Tables 4 -6) With the spread of multiresistant Gram-negative organisms, the testing of colistin is becoming more critical. Unfortunately, the disc diffusion test for colistin is unreliable and, therefore, disc criteria have been removed. If susceptibility testing is required, an MIC-based method should be used.
Piperacillin/tazobactam testing of Acinetobacter spp. (Table 5) EUCAST has determined that there is insufficient evidence that Acinetobacter spp. are a good target for piperacillin/tazobactam.
However, an MIC breakpoint has been maintained and amended to harmonize with testing of the Enterobacteriaceae. BSAC data have been used to establish appropriate zone criteria.
Glycopeptide testing of staphylococci (Table 8) Since the emergence in Staphylococcus aureus of low-level glycopeptide resistance [glycopeptide-intermediate S. aureus (GISA) and heterogeneous GISA] and vanA-mediated high-level resistance (glycopeptide-resistant S. aureus), there has been an increased focus on susceptibility testing in this situation. Studies correlating the MIC with the outcome have led to a reduction in the MIC breakpoints for vancomycin and teicoplanin to 2 mg/L. Unfortunately, the disc diffusion tests perform poorly, particularly in the identification of low-level resistance; therefore, the disc criteria have been removed. If susceptibility testing is required, an MIC-based method should be used.
Trimethoprim testing of staphylococci (Table 8) In version 9 of the method, the interpretive criteria for trimethoprim testing of staphylococci from systemic sources were removed. This followed a review of the existing data initiated when EUCAST did not set breakpoints for this combination. Data on the therapeutic efficacy of trimethoprim, when used as a sole agent for the treatment of systemic staphylococcal infections, is extremely limited, as in most countries it is only used in combination with sulfamethoxazole. In the absence of data regarding the efficacy of trimethoprim as a sole agent, it is impossible to set a clinical MIC breakpoint. However, there are indications when trimethoprim may be appropriate and BSAC guidance for the management of methicillin-resistant S. aureus (MRSA) infections does suggest trimethoprim (always in combination with an agent such as fusidic acid or rifampicin) for certain systemic infection scenarios. While there is a lack of clinical data to define breakpoints to identify isolates that may or may not respond to combination therapy, an epidemiological cut-off breakpoint based on distributions for the 'wild-type' population has been published.
Macrolide testing of staphylococci and Moraxella catarrhalis (Tables 8 and 13) It is noted that erythromycin results can be used to infer susceptibility to azithromycin, clarithromycin or roxithromycin.
Tetracycline testing of staphylococci, Streptococcus pneumoniae and b-haemolytic streptococci (Tables 8, 9 and 12)
It is noted that susceptibility to doxycycline or minocycline can be inferred from the tetracycline result. There may, however, be isolates that are resistant to tetracycline but remain susceptible to doxycycline or minocycline.
Cephalosporin testing of S. pneumoniae (Table 9) The testing of cephalosporin susceptibility has been simplified to reduce potential confusion. Reduced susceptibility to penicillin (and potentially other cephalosporins) is most reliably detected with an oxacillin 1 mg disc. Isolates categorized as susceptible 
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Andrews & Howe 
Andrews & Howe The information in bold is tentative. Breakpoints will remain tentative for 1 year from when published. If an organism is isolated from multiple sites, e.g. from blood and urine, the interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported as resistant, irrespective of the results obtained using interpretative criteria for urine isolates). c For agents not listed, criteria given for systemic isolates may be used for urinary tract isolates. Intermediate susceptibility infers that the infection may respond, as the agent is concentrated at the site of infection. d Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth.
e
In the absence of definitive organism identification, use the recommendations most appropriate for the presumptive identification, accepting that on some occasions the interpretation may be incorrect. A more cautious approach is to use the systemic recommendations. 
Miscellaneous antibiotics
The disc diffusion test is unreliable. Colistin susceptibility should be determined with an MIC method.
The information in bold is tentative. Breakpoints will remain tentative for 1 year from when published. R, resistant; I, intermediate; S, susceptible. 
b-Lactams
Most staphylococci are penicillinase producers. Benzylpenicillin will mostly, but not unequivocally, separate b-lactamase producers.
Isolates positive for b-lactamase are resistant to benzylpenicillin, phenoxymethylpenicillin, and amino-, carboxy-and ureidopenicillins. Isolates negative for b-lactamase and susceptible to cefoxitin (cefoxitin is used to screen for 'methicillin resistance') can be reported susceptible to these drugs. Isolates positive for b-lactamase and susceptible to cefoxitin are susceptible to penicillin/b-lactamase inhibitor combinations and penicillinase-resistant penicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin). Isolates resistant to cefoxitin are methicillin resistant and resistant to b-lactam agents, including b-lactamase inhibitor combinations, except for cephalosporins with approved anti-MRSA activity and clinical breakpoints. Ampicillin UTI Andrews & Howe If an organism is isolated from multiple sites, e.g. from blood and urine, the interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported resistant, irrespective of the results obtained using interpretative criteria for urine isolates). c Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth. If an organism is isolated from multiple sites, e.g. from blood and urine, the interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported resistant, irrespective of the results obtained using interpretative criteria for urine isolates). c Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth. The MIC breakpoint has changed, but a review of the data indicates that no adjustment of the zone diameter breakpoints is necessary For advice on testing susceptibility to co-trimoxazole see Appendix 1. The MIC breakpoint is based on the trimethoprim concentration in a 1: 19 combination with sulfamethoxazole.
The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. R, resistant; I, intermediate; S, susceptible. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. R, resistant; I, intermediate; S, susceptible. The information in bold is tentative and will remain so for 1 year from when published. 
Andrews & Howe
Carbapenems Doripenem 1 - 1 - - -- Ertapenem 1 - 1 - - -- Imipenem 8 4-8 2 - - --
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Andrews & Howe with the oxacillin 1 mg disc can be reported susceptible to cefepime, cefotaxime, cefpodoxime, ceftriaxone, cefuroxime+axetil and cefaclor. The cephalosporin susceptibility of isolates with reduced penicillin susceptibility is best determined using an MICbased method; therefore, the disc criteria have been removed.
Streptomycin testing of enterococci (Table 10) For the testing of high-level streptomycin resistance in enterococci, EUCAST has set a breakpoint of 512 mg/L. In fact, this breakpoint, based on testing with Mueller -Hinton media, correlates with a breakpoint of 128 mg/L when tested using Iso-Sensitest medium. Therefore, the BSAC criteria remain unchanged. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when published.
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For susceptibility testing Listeria spp., an MIC determination is advised on Iso-Sensitest agar with incubation at 35-378C in air. If a gradient method is used, the test should be undertaken following the manufacturer's instructions. In Table A3 , the MIC ranges and cut-offs for 'wild-type' strains are shown, and these can be used as an aid to interpreting susceptibility. BSAC standardized susceptibility testing method (version 10)
